RT Journal Article SR Electronic T1 Plasmodium infection induces cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.10.21256855 DO 10.1101/2021.05.10.21256855 A1 Lapidus, Sarah A1 Liu, Feimei A1 Casanovas-Massana, Arnau A1 Dai, Yile A1 Huck, John D. A1 Lucas, Carolina A1 Klein, Jon A1 Filler, Renata B. A1 Strine, Madison S. A1 Sy, Mouhamad A1 Deme, Awa B. A1 Badiane, Aida S. A1 Dieye, Baba A1 Ndiaye, Ibrahima Mbaye A1 Diedhiou, Younous A1 Mbaye, Amadou Moctar A1 Diagne, Cheikh Tidiane A1 Vigan-Womas, Inés A1 Mbengue, Alassane A1 Sadio, Bacary D. A1 Diagne, Moussa M. A1 Moore, Adam J. A1 Mangou, Khadidiatou A1 Diallo, Fatoumata A1 Sene, Seynabou D. A1 Pouye, Mariama N. A1 Faye, Rokhaya A1 Diouf, Babacar A1 Nery, Nivison A1 Costa, Federico A1 Reis, Mitermayer A1 Muenker, M. Catherine A1 Hodson, Daniel Z. A1 Mbarga, Yannick A1 Katz, Ben Z. A1 Andrews, Jason R. A1 Campbell, Melissa A1 Srivathsan, Ariktha A1 Kamath, Kathy A1 Baum-Jones, Elisabeth A1 Faye, Ousmane A1 Sall, Amadou Alpha A1 Vélez, Juan Carlos Quintero A1 Cappello, Michael A1 Wilson, Michael A1 Ben-Mamoun, Choukri A1 Somé, Fabrice A. A1 Dabiré, Roch K. A1 Moukoko, Carole Else Eboumbou A1 Ouédraogo, Jean Bosco A1 Boum, Yap A1 Shon, John A1 Ndiaye, Daouda A1 Wisnewski, Adam A1 Parikh, Sunil A1 Iwasaki, Akiko A1 Wilen, Craig B. A1 Ko, Albert I. A1 Ring, Aaron M. A1 Bei, Amy K. YR 2021 UL http://medrxiv.org/content/early/2021/05/12/2021.05.10.21256855.abstract AB Individuals with acute malaria infection generated high levels of antibodies that cross-react with the SARS-CoV-2 Spike protein. Cross-reactive antibodies specifically recognized the sialic acid moiety on N-linked glycans of the Spike protein and do not neutralize in vitro SARS-CoV-2. Sero-surveillance is critical for monitoring and projecting disease burden and risk during the pandemic; however, routine use of Spike protein-based assays may overestimate SARS-CoV-2 exposure and population-level immunity in malaria-endemic countries.Competing Interest StatementA.M.R. and Y.D. (Yale University) are named inventors on a patent application describing the REAP technology. A.M.R. is the founder of Seranova Bio. C.B.W. (Yale University) has a patent pending entitled Compounds and Compositions for Treating, Ameliorating, and/or Preventing SARS-CoV-2 Infection and/or Complications Thereof. KK, EBJ, and JS receive salary and hold stock option from Serimmune Inc.Funding StatementThis work was supported by the Fogarty International Center of the NIH (K01 TW010496), Yale School of Public Health Start-up funds, and G4 group funding (G45267, Malaria Experimental Genetic Approaches & Vaccines) from the Institut Pasteur de Paris and Agence Universitaire de la Francophonie (AUF) to AKB, NIH grants K08 AI128043 (CBW), R01 AI148467 (CBW), DGE1752134 (MSS); a Burroughs Wellcome Fund Career Award for Medical Scientists (CBW) the Ludwig Family Foundation (CBW), the Mathers Charitable Foundation (CBW); an Emergent Ventures fast grant (CBW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CAM (Cameroon): Ethical approval for this study was granted by the University of Doula Institutional Ethics Committee for Research on Human Health (Protocol No 1617), the Institutional Review Board of the Doula Military Hospital (IRB 0180776), and the Human Investigation Committee of Yale University (Protocol 2000023509). All samples were collected with informed consent and in accordance with all ethical requirements of the Institutional Review Boards of the University of Doula, Doula Military Hospital, and Yale University. SEN1 (Kédougou, Senegal): This study was conducted with ethical approval from the National Ethics Committee of Senegal (CNERS) and the Institutional Review Board of the Yale School of Public Health. All research was performed in accordance with relevant guidelines and regulations, and informed consent was obtained from all participants and/or their legal guardians. Samples used in this study were collected as part of ongoing surveillance conducted by Institut Pasteur de Dakar investigating causes of febrile illness. SEN2 (Thiès, Senegal): Ethical approval for this study was granted by the National Ethics Committee of the Ministry of Health in Senegal (Protocol SEN 14/49), the Institutional Review Board of the Harvard T.H. Chan School of Public Health (IRB 14-2830), and the Human Investigation Committee of Yale University (Protocol 2000023287). All samples were collected with informed consent and in accordance with all ethical requirements of the National Ethics Committee of Senegal, Institutional Review Board of the Harvard T.H. Chan School of Public Health, and the Human Investigation Committee of Yale University. BUR1 and BUR2 (Burkina Faso): Ethical approval for these studies was granted by the Institutional Review Boards of Centre Muraz (Ref. A003-2013/CE-CM), the Centre National de la Recherche Scientifique et Technologique (Protocols Ref. A14-2016/CEIRES; A016-2017/CEIRES) and the Human Investigation Committee of Yale University (Protocols 1209010884 and 2000021308). All samples were collected with informed consent and in accordance with all ethical requirements of the Institutional Review Boards of the Centre Muraz, CEIRES, and Yale University. GHA (Ghana): These studies were approved by the Yale University Human Investigations Committee and the Institutional Review Boards at the Noguchi Memorial Institute for Medical Research, the Ghana Health Service, and the Scientific Review Committee and the Institutional Ethics Committee at the Kintampo Health Research Center. In addition, District Ministry of Health representatives and District Ministry of Education representatives approved the study and assisted in communication with participating schools. COL1 and COL2 (Colombia): This study was approved by the Committee of Ethics in Research of the Facultad Nacional de Salud Pública (meeting of 22 May 2014) of the Universidad de Antioquia. All the study participants signed the informed consent. BRA (Brazil): Ethical approval for was granted by the Human Investigation Committee of Yale University (HIC# 1006006956) and from the CONEP in Brazil (CONEP/Brazil 45217415.4.0000.0040). NEP (Nepal): Ethical approval for this study was granted by the Nepal Health Research Council (Reg 106/2013) and the Stanford University Institutional Review Board (IRB 29992). All samples were collected with informed consent and in accordance with all ethical requirements of the Ethical Review Board of the Nepal Health Research Council and the Institutional Review Board of Stanford University. EBV (USA): This study was approved by all relevant the Institutional Review Boards (i.e., those of Northwestern University, the Ann & Robert H Lurie Children's Hospital of Chicago and DePaul University) HCW (USA): This study was approved by the Yale Human Investigation Committee, protocol #2000027690. All samples were collected with informed consent and in accordance with Yale IRB approval. YNHH (USA): A de-identified P. vivax infected blood sample was obtained under an approved protocol from the Human Investigation Committee of Yale University. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData associated with this manuscript can be found at https://doi.org/10.5061/dryad.w6m905qpj https://doi.org/10.5061/dryad.w6m905qpj